Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Herrmann

Showing results (1-10 of 229) with videos related to

Pageof 23
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 5, 2021
[Aloe vera in the prevention and treatment of radiogenic proctitis?]Thomas Herrmann
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2023
Caveat: Monoclonal antibodies 20.1 and 103.2 bind all human BTN3A proteins and are not suited to study BTN3A1-specific featuresThomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 21, 2015
[Why do cancer patients refuse curative radiation therapy?]Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 9, 2008
Second tumors after oncologic treatmentWolfgang Dörr, Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 7, 2007
Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter studyWolfgang Dörr, Thomas Herrmann,
Journal of Radiological Protection : Official Journal of the Society for Radiological Protection|October 29, 2002
Cancer induction by radiotherapy: dose dependence and spatial relationship to irradiated volumeWolfgang Dörr, Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 8, 2002
Second primary tumors after radiotherapy for malignancies. Treatment-related parametersWolfgang Dörr, Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 11, 2005
[Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation]Thomas Herrmann, Michael Baumann
Frontiers in Immunology|January 8, 2015
The Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T CellsMohindar M Karunakaran, Thomas Herrmann
Frontiers in Immunology|April 4, 2022
Butyrophilins: γδ T Cell Receptor Ligands, Immunomodulators and MoreThomas Herrmann, Mohindar M Karunakaran
Pageof 23

Showing results (1-10 of 229) with videos related to

Sort By:
Pageof 23
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 5, 2021
[Aloe vera in the prevention and treatment of radiogenic proctitis?]Thomas Herrmann
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2023
Caveat: Monoclonal antibodies 20.1 and 103.2 bind all human BTN3A proteins and are not suited to study BTN3A1-specific featuresThomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 21, 2015
[Why do cancer patients refuse curative radiation therapy?]Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 9, 2008
Second tumors after oncologic treatmentWolfgang Dörr, Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 7, 2007
Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter studyWolfgang Dörr, Thomas Herrmann,
Journal of Radiological Protection : Official Journal of the Society for Radiological Protection|October 29, 2002
Cancer induction by radiotherapy: dose dependence and spatial relationship to irradiated volumeWolfgang Dörr, Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 8, 2002
Second primary tumors after radiotherapy for malignancies. Treatment-related parametersWolfgang Dörr, Thomas Herrmann
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 11, 2005
[Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation]Thomas Herrmann, Michael Baumann
Frontiers in Immunology|January 8, 2015
The Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T CellsMohindar M Karunakaran, Thomas Herrmann
Frontiers in Immunology|April 4, 2022
Butyrophilins: γδ T Cell Receptor Ligands, Immunomodulators and MoreThomas Herrmann, Mohindar M Karunakaran
Pageof 23